论文部分内容阅读
目的:应用苯肼建立小鼠急性溶血性贫血的方法已经成熟,但用苯肼建立慢性溶血性贫血模型尚未见报道。本研究试图应用苯肼口服法建立慢性溶血性贫血动物模型并探索最适建模的苯肼浓度。方法:42只C57BL/6小鼠随机分为6组通过口服不同浓度的苯肼溶液,于口服后的第0,1,2,3,4,5,6周目内眦采集小鼠外周血检测,记录相关指标变化比较各组之间的差异,筛选出最佳慢性溶血效果的给药浓度。结果:口服苯肼溶液浓度在250 mg/L以下时C57BL/6小鼠没有出现明显的贫血状态,当浓度调至250mg/L-350mg/L时可使C57BL/6小鼠在5-7周内出现溶血性贫血症状,各组小鼠的皮肤和粘膜颜色苍白,外周血红细胞数量、血红蛋白含量、红细胞压积降低网织红细胞比例增高。但是当浓度达到350 mg/L时小鼠贫血情况过重且达不到慢性贫血的要求。当浓度为300 mg/L时小鼠各项血液指标平稳下降。结论:本实验建立了一种新的小鼠慢性贫血模型,且通过实验发现小鼠口服苯肼致慢性贫血的最佳浓度为300mg/L。据我们所知,这是首次使用苯肼建立慢性贫血的动物模型,此模型对研究人类慢性贫血具有重要价值。
PURPOSE: To establish a method for establishing acute hemolytic anemia in mice by using phenylhydrazine. However, it has not been reported to establish chronic hemolytic anemia model by phenylhydrazine. This study attempts to establish a model animal model of chronic hemolytic anemia using phenylhydrazine oral administration and explore the optimum model of phenylhydrazine concentration. Methods: Forty-two C57BL / 6 mice were randomly divided into 6 groups: mice were orally administered with different concentrations of phenylhydrazine solution, and the peripheral blood of mice was collected at the 0th, 1st, 2nd, 3rd, 4th, Detect, record the changes of relevant indicators compare the differences between the various groups, screening for the best chronic hemolytic effect of the drug concentration. Results: There was no obvious anemia in C57BL / 6 mice when the oral concentration of phenylhydrazine solution was below 250 mg / L. When the concentration was adjusted to 250mg / L to 350mg / L, C57BL / 6 mice were treated at 5-7 weeks Symptoms of hemolytic anemia appeared within each group of mice skin and mucous membrane pale, the number of peripheral red blood cells, hemoglobin content, hematocrit decreased reticulocyte increased. However, when the concentration of 350 mg / L mouse anemia is too heavy and not meet the requirements of chronic anemia. When the concentration of 300 mg / L mice blood indicators decreased steadily. Conclusion: This study established a new mouse model of chronic anemia and found that the optimal concentration of phenylhydrazine for chronic anemia was 300 mg / L. To our knowledge, this is the first animal model to establish chronic anemia using phenylhydrazine. This model is of great value in the study of human chronic anemia.